Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BL-B01D1 |
| Synonyms | |
| Therapy Description |
BL-B01D1 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting EGFR and ERBB3 (HER3) linked to a topoisomerase I inhibitor, which potentially decreases tumor growth (PMID: 38823410). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BL-B01D1 | BL B01D1|BLB01D1|BMS986507|BMS 986507|BMS-986507|Izalontamab brengitecan | EGFR Antibody 72 HER3 (ERBB3) Antibody 28 | BL-B01D1 is an antibody-drug conjugate (ADC) comprising a bispecific antibody targeting EGFR and ERBB3 (HER3) linked to a topoisomerase I inhibitor, which potentially decreases tumor growth (PMID: 38823410). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07100080 | Phase II | Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium BL-B01D1 | Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | Recruiting | USA | ROU | POL | NOR | NLD | ITA | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BEL | ARG | 10 |
| NCT07106762 | Phase II | Cisplatin + Gemcitabine Carboplatin + Gemcitabine BL-B01D1 | Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy | Recruiting | USA | SWE | ROU | NOR | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 2 |
| NCT06926868 | Phase II | Paclitaxel BL-B01D1 Capecitabine Nab-paclitaxel Carboplatin + Gemcitabine | A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | Recruiting | USA | TUR | SWE | ROU | POL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | AUT | AUS | ARG | 10 |
| NCT05983432 | Phase I | BL-B01D1 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | Recruiting | USA | 0 |
CKB BOOST